Browsing Category
Pharma Industry News
4534 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Lupin adds Yuvezzi to €190m VISUfarma bet as European ophthalmology strategy takes shape
Lupin has secured exclusive Yuvezzi rights across major European markets through VISUfarma, extending its €190 million ophthalmology investment into a differentiated prescription therapy that still requires regional approvals.
A $50m quarter changes the stakes for UroGen as UGN-103 reaches FDA
UroGen files UGN-103 with the FDA as ZUSDURI sales surge 73%, potentially extending its fast-growing bladder cancer franchise into 2044.
Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.32bn in rare epilepsy expansion
Jazz Pharmaceuticals is committing $820 million upfront for Actio Biosciences and ABS-1230, placing a sizeable bet on a genetically targeted epilepsy therapy whose ongoing Phase 1b/2a study could potentially support a U.S. approval filing.
Fulcrum Therapeutics agrees reverse merger with Slate Medicines and $270m dividend
Fulcrum's $270m dividend and 5% stub hand Slate a Nasdaq listing, but SLTE-1009's PACAP bet must beat CGRP incumbents to justify a $350m valuation.
Mesoblast completes 350-patient Phase 3 treatment as mid-2027 back pain readout becomes next valuation test
Mesoblast has completed treatment of 350 Phase 3 back pain patients, putting rexlemestrocel-L on course for a pivotal mid-2027 efficacy readout.
PMV’s $79.4m cash pile now hinges on rezatapopt’s 2027 ovarian cancer FDA bid
PMV completes key rezatapopt enrollment with a 2027 FDA filing ahead as its $79.4m cash balance exceeds its current market value.
New Alzheimer’s imaging approval could help unlock Lantheus’ neurology merger payouts
TAUKLARIFY wins FDA approval as Lantheus expands its Alzheimer’s imaging franchise ahead of Curium’s $8bn acquisition and neurology CVR targets.
RESTORE trial could turn NVG-291 into NervGen’s defining spinal cord injury asset
NVG-291 heads into Phase 3 as NervGen deploys its $61m cash runway behind a 150-patient test of hand-function recovery in chronic tetraplegia.
Fate Therapeutics bets on outpatient CAR T as FT819 enters potentially registrational study
FT819 enters a potentially registrational lupus nephritis trial with outpatient dosing as Fate tests whether off-the-shelf CAR T can scale.
Sagimet’s acne strategy enters its biggest test after FDA clears denifanstat Phase 3
FDA clearance sends denifanstat into an 800-patient U.S. Phase 3 as Sagimet deploys its $257.6m cash base. See what the pivotal test means.